Synlogic Inc (SYBX)

Nov 12, 2024, 4:35 PM EST - 5 months ago

Synlogic Reports Third Quarter 2024 Financial Results

Aug 8, 2024, 7:00 AM EDT - 9 months ago

Synlogic Reports Second Quarter 2024 Financial Results

May 14, 2024, 7:00 AM EDT - 1 year ago

Synlogic Reports First Quarter 2024 Financial Results

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 12:15 PM EST - 1 year ago

Synlogic Adopts Limited Duration Stockholders Rights Plan

Feb 8, 2024, 4:15 PM EST - 1 year ago

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

Feb 2, 2024, 12:00 PM EST - 1 year ago

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Jan 4, 2024, 7:00 AM EST - 1 year ago

Synlogic Provides Corporate Update and Outlook for 2024

Dec 27, 2023, 7:00 AM EST - 1 year ago

Synlogic Announces Contract with the Air Force Research Lab

Dec 7, 2023, 7:00 AM EST - 1 year ago

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

Nov 9, 2023, 7:00 AM EST - 1 year ago

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 3, 2023, 4:15 PM EDT - 1 year ago

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering

Sep 29, 2023, 7:00 AM EDT - 1 year ago

Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

Sep 28, 2023, 11:15 AM EDT - 1 year ago

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

Sep 27, 2023, 12:30 PM EDT - 1 year ago

Synlogic Announces Reverse Stock Split

Sep 21, 2023, 7:00 AM EDT - 1 year ago

Synlogic to Participate in Chardan's Genetic Medicines Conference

Sep 19, 2023, 11:00 AM EDT - 1 year ago

Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 11, 2023, 7:00 AM EDT - 1 year ago

Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria

Jun 28, 2023, 7:00 AM EDT - 1 year ago

Synlogic Announces International Nonproprietary Name Selection for SYNB1934

Jun 27, 2023, 7:00 AM EDT - 1 year ago

Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum

Jun 8, 2023, 6:45 AM EDT - 2 years ago

Synlogic Reminds Stockholders of 2023 Annual General Meeting Details

Jun 5, 2023, 6:45 AM EDT - 2 years ago

Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

May 24, 2023, 6:35 AM EDT - 2 years ago

Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

May 23, 2023, 6:50 AM EDT - 2 years ago

Synlogic to Present at the Jefferies Global Healthcare Conference

May 11, 2023, 6:50 AM EDT - 2 years ago

Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update

May 9, 2023, 6:50 AM EDT - 2 years ago

Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria

Mar 29, 2023, 6:40 AM EDT - 2 years ago

Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

Mar 28, 2023, 6:52 AM EDT - 2 years ago

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria

Mar 20, 2023, 6:55 AM EDT - 2 years ago

Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Mar 7, 2023, 6:57 AM EST - 2 years ago

Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Jan 24, 2023, 6:57 AM EST - 2 years ago

Synlogic Announces Participation in Upcoming Investor and Industry Conferences

Jan 19, 2023, 6:58 AM EST - 2 years ago

Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)

Jan 5, 2023, 6:58 AM EST - 2 years ago

Synlogic Provides Corporate Update and Outlook for 2023

Jan 3, 2023, 6:58 AM EST - 2 years ago

Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

Dec 15, 2022, 6:59 AM EST - 2 years ago

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

Nov 30, 2022, 4:15 PM EST - 2 years ago

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Nov 10, 2022, 6:59 AM EST - 2 years ago

Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 18, 2022, 6:59 AM EDT - 2 years ago

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

Sep 6, 2022, 7:00 AM EDT - 2 years ago

Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease

Aug 23, 2022, 7:00 AM EDT - 2 years ago

Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)

Aug 11, 2022, 1:41 PM EDT - 2 years ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 7:05 AM EDT - 2 years ago

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

DNA

Aug 11, 2022, 6:58 AM EDT - 2 years ago

Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

Jul 12, 2022, 7:00 AM EDT - 3 years ago

Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

Jun 29, 2022, 7:00 AM EDT - 3 years ago

Synlogic Announces Appointment of General Counsel and Corporate Secretary

Jun 28, 2022, 7:00 AM EDT - 3 years ago

Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference

Jun 21, 2022, 7:00 AM EDT - 3 years ago

Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference

May 12, 2022, 12:54 PM EDT - 3 years ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2022 Results - Earnings Call Transcript

May 12, 2022, 7:00 AM EDT - 3 years ago

Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update